NCT06255639

Brief Summary

In patients with Multiple Myeloma (MM), bone lesions can lead to multiple vertebral lesions, with vertebral collapses. The introduction of minimally invasive procedures such as percutaneous vertebroplasty allow patients to return to a fair level of function and a significant reduction in pain. Despite medical therapies, radiotherapy, analgesics and vertebroplasty procedures, patients with multiple spinal injuries often complain of pain and stiffness that limit their mobility, daily activities and work. The aim of this study is to measure how the biomechanical, thermo-metabolic and algic parameters change after vertebroplasty in patients with MM

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 15, 2020

Completed
3.3 years until next milestone

First Submitted

Initial submission to the registry

January 19, 2024

Completed
25 days until next milestone

First Posted

Study publicly available on registry

February 13, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2024

Completed
Last Updated

February 13, 2024

Status Verified

February 1, 2024

Enrollment Period

4 years

First QC Date

January 19, 2024

Last Update Submit

February 2, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Difference in mean of kinematic data for walking before and after vertebroplasty

    Difference in mean of kinematic data for walking before and after vertebroplasty

    2 months

  • difference in mean of movement range for affected joints before and after vertebroplasty

    difference in mean of movement range for affected joints before and after vertebroplasty

    2 months

  • Difference in mean of energy expenditure before and after vertebroplasty

    Difference in mean of energy expenditure before and after vertebroplasty

    2 months

Secondary Outcomes (5)

  • To explore the impact of vertebroplasty on thermal parameters

    2 months

  • To explore the impact of vertebroplasty on metabolic parameters

    2 months

  • To explore the impact of vertebroplasty on metabolic parameters

    2 months

  • To explore the impact of vertebroplasty on metabolic parameters

    2 months

  • To explore the impact of vertebroplasty on pain

    2 months

Study Arms (1)

MM patient candidate to vertebroplasty

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients suffering from multiple myeloma (MM) with multiple vertebral lesions and candidates for vertebroplasty, consecutively diagnosed with MM in the period from 2015 to 2021 at the study center

You may qualify if:

  • Age≥ 18 years;
  • Diagnosis of multiple myeloma;
  • Clinical indication and eligibility for vertebroplasty procedure;
  • Performance Status (ECOG) 0-2;
  • Life expectancy greater than three months;
  • Low-resolution full skeletal CT scan at disease onset and/or at follow-up;
  • Spine pain with stiffness and functional impediment pre vertebroplasty;
  • Able to express appropriate consent for participation in the study (e.g. Able to understand Italian, patient with intact cognitive abilities)

You may not qualify if:

  • presence of spinal cord compressions;
  • unstable spinal injuries, requiring an orthopaedic back brace;
  • risk of spinal cord injury;
  • body mass index BMI\>28 kg/m2.
  • absence of signed informed consent form

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS

Aviano, Pordenone, 33081, Italy

RECRUITING

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Mariagrazia Michieli, MD

    Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mariagrazia Michieli, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 19, 2024

First Posted

February 13, 2024

Study Start

October 15, 2020

Primary Completion

October 1, 2024

Study Completion

October 1, 2024

Last Updated

February 13, 2024

Record last verified: 2024-02

Locations